Skip to main content
. 2023 Apr 3;11(4):786. doi: 10.3390/vaccines11040786

Figure 4.

Figure 4

Post-vaccination anti-SARS-CoV-2 IgG titers (A) and IFN-γ levels (B) in relation to absolute lymphocyte counts: >800 cells/μL (gray dot), 500–799 cells/μL (red dot) and <500 cells/μL (green dot). (A) The lower dotted line marks anti-spike IgG antibody titers considered positive (7.1 BAU/mL), and the upper dotted line marks anti-spike IgG antibody titers considered protective (260 BAU/mL). (B) Dotted line marks IFN-γ levels of 80 pg/mL that were considered positive. ALEM: alemtuzumab; CLAD: cladribine; FING: fingolimod; FLT: first-line therapies; NATA: natalizumab; NTP: non-treated patients; OCRE: ocrelizumab; RITU: rituximab.